SANA earnings date and last-quarter result: next report 2026-08-10, last quarter beat, P/E -3.35. Updated 2026-07-23.
Sana Biotechnology (SANA) Research Hub
Sana Biotechnology (SANA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.36 USD (+1.29%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -3.35, market cap 0.87B. This hub links to the full technical, earnings and options research available for SANA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.36 USD (+1.29%) |
| 52-week range | 2.225 USD – 4.19 USD |
| Trend regime | Range |
| 14-day RSI | 32.3 (Bearish) |
| Trailing P/E | -3.35 |
| Market cap | 0.87B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for SANA
Covered Call on SANA: how it works, illustrative setup around the real 2.36 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on SANA: how it works, illustrative setup around the real 2.36 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on SANA: how it works, illustrative setup around the real 2.36 USD price, max profit/loss, breakeven and when to use it. Educational.
SANA technical analysis: range, last 2.36 USD, RSI 32.3, 52w range 2.225 USD–4.19 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is SANA in?
Sana Biotechnology (SANA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is SANA in an uptrend or downtrend?
As of 2026-10-26, SANA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is SANA's trailing P/E ratio?
SANA's trailing P/E is -3.35, with a market cap of 0.87B. See the earnings research page for full valuation detail.
When does SANA next report earnings?
SANA is next scheduled to report earnings on 2026-08-10.